| Autor: |
Fatemeh, Kaghazchi, Austin J, Borja, Emily C, Hancin, Abhijit, Bhattaru, Donald K E, Detchou, Siavash Mehdizadeh, Seraj, Chaitanya, Rojulpote, Soren, Hess, Lorenzo, Nardo, Peter E, Gabriel, Scott M, Damrauer, Thomas J, Werner, Abass, Alavi, Mona-Elisabeth, Revheim |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Am J Nucl Med Mol Imaging |
| ISSN: |
2160-8407 |
| Popis: |
Cancer patients are at markedly increased risk for venous thromboembolism (VTE). Early detection of VTE may decrease morbidity and mortality in this population. We conducted this study to evaluate the ability of FDG-PET/CT to detect thrombosis in cancer patients. This retrospective study included 131 cancer patients with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) referred for 2-deoxy-2-[(18)F]-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT). All subjects underwent PET/CT imaging 60 minutes after FDG injection. Images were visually assessed for increased FDG uptake within the venous lumen. For positive cases, clinical follow-up and Doppler ultrasonography and/or contrast-enhanced CT scans were reviewed. FDG-PET/CT revealed abnormal uptake in the venous system of 26 (19.8%) patients. Eighteen (69.2%) had a history of DVT, and 13 (50%) had a history of PE. The most common site of thrombosis was the inferior vena cava (IVC) (n=14, 53.8%), followed by lower extremities veins (n=9, 34.6%), jugular veins (n=2, 7.7%), and superior vena cava (n=1, 3.8%). The presence of thrombi was confirmed by reviewing clinical follow-up in 6 (23.1%) patients. Among this group, thrombosis was detected in lower extremity veins (n=4, 15.8%), jugular veins (n=1, 3.8%), and IVC (n=1, 3.8%). Our study demonstrates that thrombi prior to their clinical manifestation can be detected by FDG-PET/CT in cancer patients. Moving forward, physicians must carefully consider the venous system when reporting FDG-PET/CT for cancer patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
